Such effects could potentially contribute to the observations of reduced GLP-1 plasma levels in obese and diabetic patients, indirectly impeding the ability of the β-cell to compensate for insulin resistance through increased insulin secretion. This evidence concerns the gene GCG and Insulin resistance.